Printer Friendly

THE IMMUNE RESPONSE CORPORATION APPOINTS VICE PRESIDENTS OF RESEARCH AND REGULATORY AFFAIRS

 THE IMMUNE RESPONSE CORPORATION APPOINTS VICE PRESIDENTS
 OF RESEARCH AND REGULATORY AFFAIRS
 SAN DIEGO, June 1 /PRNewswire/ -- The Immune Response Corporation (NASDAQ-NMS: IMNR) today announced the appointment of Steven W. Brostoff, Ph.D. as vice president, Research and Development; Fred C. Jensen, D.V.M. as vice president, Research and Development, Virology; and Steven P. Richieri as vice president, Medical and Regulatory Affairs.
 Brostoff has served as executive research director of autoimmune diseases for Immune Response since 1988. During his time with Immune Response, he has been instrumental in developing the proprietary technology currently employed in the company's autoimmune disease program. This program is developing potential treatments for rheumatoid arthritis, multiple sclerosis and type I diabetes. Prior to joining the company, Brostoff was professor and associate dean of University Research Development with the Medical University of South Carolina, where he retains a faculty appointment. Dr. Brostoff also holds positions as adjunct professor of pathology at the University of California, San Diego, and adjunct professor of neurology at the University of California, Irvine. He received a bachelor of science degree and a Ph.D. from the Massachusetts Institute of Technology in Cambridge.
 Jensen has served as executive research director of virology for Immune Response since 1988. Jensen has been primarily responsible for the study of HIV and other retrovirus infections. He has led Immune Response's research team developing the HIV therapeutic vaccine, currently in nationwide Phase II/III clinical trials sponsored by a joint venture with Rhone-Poulenc Rorer Inc. (NYSE: RPR). Jensen has more than 30 years experience in retrovirus research. Prior to joining Immune Response he served as associate member in the department of immunopathology at the Research Institute of Scripps Clinic, La Jolla, Calif., and as an associate member in the departments of Experimental Pathology and Immunopathology at the Scripps Clinic & Research Foundation, La Jolla. Jensen has also held the position of senior vice president in charge of virology with CytoTech Inc. of San Diego. He received a D.V.M. from the University of Brno, Czechoslovakia.
 Richieri has served as executive director, medical and regulatory affairs, for Immune Response since 1991, where he has been responsible for the company's Food and Drug Administration (FDA) interactions, developing regulatory strategies, and directing all clinical research and product development activities. Prior to joining Immune Response, Richieri was vice president, regulatory and technical affairs, with Dura Pharmaceuticals (formerly Immunetech Pharmaceuticals) of San Diego and was research and regulatory affairs associate with Barnes Hind Inc. of San Diego. Richieri received a bachelor of science degree from Rutgers College of Pharmacy, New Brunswick, and a master of business administration from the University of San Diego.
 The Immune Response Corporation is a biopharmaceutical company engaged in the development of products for the treatment of HIV infection, which leads to AIDS, and for the treatment of certain major autoimmune diseases, particularly rheumatoid arthritis, multiple sclerosis and insulin-dependent diabetes.
 -0- 5/29/92
 /CONTACT: Steven L. Basta, director of investor relations of THE Immune Response Corporation, 619-431-7080/
 (IMNR) CO: The Immune Response Corporation ST: California IN: MTC SU: PER


JL-KJ -- SD003 -- 5489 06/01/92 08:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 1, 1992
Words:521
Previous Article:PATLEX CORP., AUTOFINANCE GROUP APPROVE PROPOSED MERGER
Next Article:AUTOFINANCE GROUP AND PATLEX ANNOUNCE APPROVAL OF PROPOSED MERGER
Topics:


Related Articles
IMMULOGIC APPOINTS SENIOR DIRECTOR, REGULATORY AFFAIRS
THE IMMUNE RESPONSE CORPORATION APPOINTS VICE PRESIDENT OF ADMINISTRATION
MICROPROBE CORPORATION NAMES CEO AND PRESIDENT, COO
IVAX ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT BAKER NORTON PHARMACEUTICALS
IVAX ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT BAKER NORTON PHARMACEUTICALS
THE IMMUNE RESPONSE CORPORATION ANNOUNCES ADDITION OF DR. MELVIN PERELMAN TO ITS BOARD OF DIRECTORS
MEDAREX ANNOUNCES THE APPOINTMENT OF RANDALL T. CURNOW, M.D. AS SENIOR VICE PRESIDENT AND MEDICAL DIRECTOR

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters